Aquestive Therapeutics, Inc. (AQST)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues | 10,003 | 8,720 | 13,542 | 20,099 |
| Selling, general and administrative | 12,705 | 19,072 | 12,126 | 11,356 |
| Research and development | 4,105 | 5,361 | 5,269 | 4,162 |
| Manufacture and supply | 4,561 | 3,652 | 4,437 | 4,526 |
| Total costs and expenses | 21,371 | 28,085 | 21,832 | 20,044 |
| Loss from operations | -11,368 | -19,365 | -8,290 | 55 |
| Interest expense | 2,781 | 2,782 | 2,780 | - |
| Interest expense related to the sale of future revenue | 61 | 59 | 59 | 58 |
| Interest income and other income, net | 2,096 | 713 | 979 | 1,395 |
| Interest expense related to royalty obligations | 1,434 | 1,437 | 1,359 | 1,358 |
| Interest expense | - | - | - | 2,779 |
| Net loss before income taxes | -13,548 | -22,930 | -11,509 | -2,745 |
| Net loss | -13,548 | -22,930 | -11,509 | -2,745 |
| Comprehensive loss | -13,548 | -22,930 | -11,509 | -2,745 |
| Basic (in dollars per share) | -0.14 | -0.24 | -0.13 | -0.03 |
| Basic (in shares) | 99,326,701 | 95,497,056 | 91,082,081 | 90,911,626 |
| Diluted (in dollars per share) | -0.14 | -0.24 | -0.13 | -0.03 |
| Diluted (in shares) | 99,326,701 | 95,497,056 | 91,082,081 | 90,911,626 |